Comparative Pharmacology
Head-to-head clinical analysis: AVC versus SULFAIR 10.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AVC versus SULFAIR 10.
AVC vs SULFAIR 10
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
AVC (sulfanilamide) is a sulfonamide antibiotic that inhibits bacterial dihydrofolate synthesis by competing with para-aminobenzoic acid (PABA), thereby blocking folic acid production and bacterial growth.
Bacteriostatic inhibitor of dihydropteroate synthase, blocking folic acid synthesis in susceptible bacteria.
1 applicatorful (approximately 5 g of 0.1% cream) intravaginally once daily at bedtime for 7 days.
5 mg orally once daily, taken at bedtime.
None Documented
None Documented
3-5 hours; prolonged in renal impairment (up to 12 hours).
Terminal elimination half-life of 8-12 hours in adults with normal renal function (CrCl >60 mL/min); extends to 20-30 hours in severe renal impairment (CrCl <30 mL/min), requiring dose adjustment.
Renal: 30-50% unchanged; biliary/fecal: 10-20% as metabolites.
Renal excretion of unchanged drug (approximately 70-80%) and hepatic metabolism (20-30% as metabolites). Fecal elimination is minimal (<5%).
Category C
Category C
Antibiotic (Sulfonamide)
Antibiotic (Sulfonamide)